EBOLA: BIOCRYST PHARMACEUTICAL WINS UNITED STATES CONTRACT FOR EBOLA DRUG

Biocryst Pharmaceutical has won an 18 month contract from United States Government to continue the development of drugs for treatment of Ebola and other viral diseases.

The contract has a base value of $12.1 million to support manufacturing and up to $22.9 million in condition financing.

The drug, BCX4430 is at an early stage of testing by healthy volunteers. Other companies testing potential treatment for Ebola are Glaxo Smithkline, Sarepta Pharmaceuticals Inc, Novavax Inc, Merck and Co and Johnson and Johnson.

culled from Reuters